SPRY
ARS Pharmaceuticals, Inc.10.66
+0.07+0.66%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Granular Q&A on refills, coverage
Q&A drilled into execution details, largely reaffirming prepared remarks on neffy's refill-heavy market challenges. Management specified sales force expansion funding from slashed advertising, market research, conferences, and rep perks—SG&A stays flat. Get neffy fuels over 10% of scripts, with trends accelerating. Coverage broadens post-July 1 via Caremark, plus Medicaid gains. Refills emerge modestly now, ramping H2 2026 as lots expire. DTC spend holds near $100M; inventory days comfortable into back-to-school. Analysts got straight answers; watch refill conversion.
Key Stats
Market Cap
1.05BP/E (TTM)
-Basic EPS (TTM)
-0.81Dividend Yield
0%Recent Filings
10-K
FY2025 10-K excerpt
ARS Pharmaceuticals' 10-K for FY2025 ended December 31, 2025, provides no financial statements, revenue, profitability, or quarterly breakdowns in the cover page excerpt. Lacks topline figures, EPS, margins, cash flows, or segment results. No Q4 metrics or y/y deltas disclosed. No non-GAAP metrics defined or reconciled. No debt, liquidity, or capital allocation details. No annual guidance provided. Regulatory approval delays pose a key risk to future momentum.
8-K
neffy nets $72.2M in 2025
10-Q
Q3 FY2025 results
ARS Pharma ramped neffy product revenue to $31.3M in Q3 ended September 30, 2025, up from $0.6M y/y, driving total revenue to $32.5M (y/y +1470%, derived). Yet SG&A exploded to $74.8M on marketing and sales buildout, yielding a $53.2M operating loss, widened from $21.7M y/y, with net loss at $51.2M or $(0.52) diluted EPS on 98.8M shares. Cash equivalents hit $59.6M and short-term investments $228.7M, bolstered by $97.8M net term loan proceeds (9.49% rate, due 2030); operating cash burn was $127.4M YTD. Closed $100M Term A Loan in September 2025. neffy needs broad payor coverage to counter entrenched injectables.
8-K
neffy hits $31.3M Q3 sales
8-K
ARS inks $250M debt facility
ARS Pharmaceuticals secured a $250M term loan facility on September 29, 2025, drawing $100M initially from RA Capital and OMERS affiliates to fund neffy development and commercialization plus general corporate needs. Loans mature in five years at SOFR-plus-5.50% (floored at 3%), with PIK options and revenue-based rate cuts; further $150M tranches hinge on timelines and neffy hitting $100M TTM revenue. Collateralized by all assets, it bolsters runway while covenants curb flexibility.
ARMP
Armata Pharmaceuticals, Inc.
5.72-0.44
ARQT
Arcutis Biotherapeutics, Inc.
28.53-0.42
ASBP
Aspire Biopharma Holdings, Inc.
0.10-0.00
JSPR
Jasper Therapeutics, Inc.
1.71+0.07
NKTR
Nektar Therapeutics
49.16-4.14
NRSN
NeuroSense Therapeutics Ltd.
0.85+0.01
NSRX
Nasus Pharma Ltd.
6.80+0.00
RPRX
Royalty Pharma plc
38.38-0.15
SEPSF
ASEP Medical Holdings Inc.
0.01+0.00
TARS
Tarsus Pharmaceuticals, Inc.
78.28-2.20